80418-13-9Relevant articles and documents
Trifluoromethyl reagent as well as synthesis method and application thereof
-
Paragraph 0105-0109, (2022/01/08)
The invention discloses a trifluoromethyl reagent as well as a synthesis method and application thereof, wherein the structural formula of the trifluoromethyl reagent is as shown in formula I in the specification. According to the invention, diphenyl trifluoromethylphosphine and iodomethane are used as raw materials, and are heated in an organic solvent to carry out an addition reaction to prepare the trifluoromethylation reagent. The method is simple and convenient in process, high in yield and capable of realizing 10-gram-level large-scale preparation; more importantly, the trifluoromethylation reagent can be used as a free radical and a nucleophilic reagent to be applied to free radical addition reaction and simple nucleophilic addition reaction to prepare different types of trifluoromethylation products, so that the method has important application value.
Highly enantioselective construction of CF3-bearing all-carbon quaternary stereocenters: Hiral spiro-fused bisoxazoline ligands with 1,1′-binaphthyl sidearm for asymmetric Michael-type Friedel-Crafts reaction
Bao, Robert Li-Yuan,Fu, Kang,Shi, Lei
supporting information, (2021/11/27)
A novel class of chiral spiro-fused bisoxazoline ligands possessing a deep chiral pocket was prepared. The developed ligands have been employed in the nickel-catalyzed highly enantioselective Michael-type Friedel-Crafts reaction, affording the products bearing a trifluoromethylated all-carbon quaternary stereocenter with moderate to excellent yields (up to 99%) and good to excellent enantioselectivies (up to > 99.9% ee). Moreover, a proposed model of chiral pocket revealed that the attack of indole from the Re-face of β-CF3-β-disubstituted nitroalkene was favorable.
Process Development of Tryptophan Hydroxylase Inhibitor LX1031, a Drug Candidate for the Treatment of Irritable Bowel Syndrome
Bednarz, Mark S.,Iimura, Shinya,Kanamarlapudi, Ramanaiah C.,Lim, Ngiap-Kie,Wu, Wenxue,Yan, Jie,Zhang, Haiming,Zhao, Matthew M.
, p. 261 - 273 (2020/03/10)
Two process routes for LX1031, a tryptophan hydroxylase inhibitor for the treatment of irritable bowel syndrome, were developed. They shared the same left-hand and right-hand starting materials as well as the penultimate intermediate. The chiral center in